Jasper Therapeutics Inc. (JSPR)
JSPR trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | JSPR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001788028 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern." | 10-Q 2026-08-14 |
| Cash and burn | $7.3M cash; operating cash flow -$15.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | 1,109,152 (2026-08-10); 16,253,332 a year earlier; 110,800,413 three years earlier. 3y figure adjusted for splits (1-for-10 overall). | Cover page 2026-08-10 |
| Reverse splits, 3 years | 2; latest 1-for-30 on 2026-11-06 | Source 2026-11-06 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-14 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-06-09 |
| Delisting | 25-NSE filed | 25-NSE 2026-09-24 |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-04-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$2.8M | -$6.9M | $7.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$1.2M | -$14.5M | $14.1M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$9.1M | -$21.9M | $28.7M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$18.7M | -$17.0M | $50.9M | No debt tags | Needs four quarters | 10-Q 2025-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$26.7M | -$15.5M | $39.5M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$21.2M | -$22.8M | $48.8M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | -$24.3M | -$21.1M | $71.6M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$18.6M | -$14.1M | $92.5M | No debt tags | Needs four quarters | 10-Q 2025-11-10 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-3 | 2026-10-14 |
| Latest annual report AMENDMENT NO. 1 TO FORM 10-K | 10-K/A | 2026-04-30 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-16 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-10-19 |
Source: SEC EDGAR submissions feed, 489 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -18.9% |
| 1 month | -8.1% |
| 3 months | -47.2% |
| Year to date | -75.1% |
| 1 year | -71.7% |
| From 52-week high | -77.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DYAI | Dyadic International Inc. | $0.3200 | -2.14% | $12.8M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
| ATYR | aTyr Pharma Inc. | $5.24 | -14.17% | $13.4M |
| BCDA | BioCardia Inc. | $0.7901 | -4.92% | $12.0M |
| PLUR | Pluri Inc. | $1.04 | -0.95% | $15.0M |
| ABOS | Acumen Pharmaceuticals Inc. | $0.2160 | +0.93% | $15.6M |
| SCLX | Scilex Holding Company | $1.25 | -12.59% | $10.6M |
| ALGS | Aligos Therapeutics Inc. | $1.66 | -20.95% | $10.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier